RIP1/RIP3/MLKL activator 1

RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability[1].

Product Specifications

CAS Number

[2682850-41-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Mixed Lineage Kinase; Necroptosis; RIP kinase

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rip1-rip3-mlkl-activator-1.html

Purity

97.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(C(C=C2C1=CC=C3[C@]4(CC[C@]5(CC[C@@](C(NCC6=CN(N=N6)CC7=CC=C(C=C7)C(C)(C)C)=O)(CC5[C@@]4(CC[C@@]23C)C)C)C)C)=O)O

Molecular Formula

C43H56N4O3

Molecular Weight

676.93

Precautions

H302, H315, H319, H335

References & Citations

[1]Yao Feng, et al. Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis. Eur J Med Chem. 2022 Feb 5;229:114070.